Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,386 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Pathologies Clear all
Completed No phase listed Observational

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

NCT05974852
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Ocrelizumab
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
732 participants
Timeline
2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 2 Interventional Results available

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555
View directory record Official record
Conditions
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions
Siltuximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 3 Interventional Results available

12-week Efficacy of Indacaterol

NCT01072448
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 75 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
62
States / cities
Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Nov 7, 2026, 2:22 AM EST
Terminated No phase listed Observational

The Use of CT to Identify Damaged Heart Muscle in Patients Undergoing Ventricular Tachycardia Ablation.

NCT00583284
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Nov 7, 2026, 2:22 AM EST
Active, not recruiting Not applicable Interventional

Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation

NCT05351333
View directory record Official record
Conditions
Spinal Cord Injuries, Polytrauma, Burns
Interventions
placebo
Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 4 Interventional Results available

An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain

NCT00465647
View directory record Official record
Conditions
Postoperative Pain
Interventions
Hydromorphone
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
28 Days to 16 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • Orange, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Nov 7, 2026, 2:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot
Interventions
Human split thickness skin allograft, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing
Other
Lead sponsor
Professional Education and Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • O'Fallon, Illinois • Youngstown, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Nov 7, 2026, 2:22 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 7, 2026, 2:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Care for Patients With PSP and Related Disorders

NCT03552484
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Syndrome, Atypical Parkinson Disease
Interventions
Home Visit Program, Usual Care/Online Survey
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 1 Interventional

Safety of RG2077 in Patients With Multiple Sclerosis

NCT00076934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
RG2077 (CTLA4-IgG4m)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Nov 7, 2026, 2:22 AM EST
Recruiting No phase listed Observational

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

NCT05705219
View directory record Official record
Conditions
Liver Cancer, Adult
Interventions
3D-MPUS
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Palo Alto, California • San Diego, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Nov 7, 2026, 2:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Study of a Holistic Health Program for United Methodist Clergy

NCT01564719
View directory record Official record
Conditions
Obesity, Depression, Diabetes, Hypertension, Hypercholesterolemia
Interventions
Holistic health
Behavioral
Lead sponsor
Duke Clergy Health Initiative
Other
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Nov 7, 2026, 2:22 AM EST
Terminated Phase 1 Interventional Results available

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

NCT03168438
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Letetresgene autoleucel with pembrolizumab, Fludarabine, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 2 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Nov 7, 2026, 2:22 AM EST
Not listed Phase 1 Interventional

Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection

NCT00050765
View directory record Official record
Conditions
Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Interventions
MyoCell™ Autologous Myoblasts
Drug
Lead sponsor
Bioheart, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2006 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 7, 2026, 2:22 AM EST
Completed Not applicable Interventional

Lateral Branch Cooled Radiofrequency Denervation vs. Conservative Therapy for Sacroiliac Joint Pain

NCT03601949
View directory record Official record
Conditions
Sacroiliac Joint Pain
Interventions
SInergy Cooled Radiofrequency, Medical Management
Device · Other
Lead sponsor
Avanos Medical
Other
Eligibility
21 Years to 110 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Bloomington, Illinois • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Nov 7, 2026, 2:22 AM EST
Terminated Not applicable Interventional

Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes

NCT04271930
View directory record Official record
Conditions
Sleep, Multiple Myeloma
Interventions
Mindfulness Awareness Practices for Insomnia, Sleep Health Information
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03202992
View directory record Official record
Conditions
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
27 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Nov 7, 2026, 2:22 AM EST
Recruiting Phase 3 Interventional

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

NCT07482787
View directory record Official record
Conditions
Epidermolysis Bullosa (EB)
Interventions
SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Paradigm Therapeutics
Industry
Eligibility
28 Days to 12 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Rancho Santa Margarita, California • Redwood City, California • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

NCT02678793
View directory record Official record
Conditions
Morton's Neuroma
Interventions
CNTX-4975
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • El Cajon, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Nov 7, 2026, 2:22 AM EST
Active, not recruiting Phase 1 Interventional

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04756726
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Non-Hodgkin's
Interventions
cemsidomide, Dexamethasone Oral
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Nov 7, 2026, 2:22 AM EST
Completed Phase 1Phase 2 Interventional Results available

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035
View directory record Official record
Conditions
Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
Interventions
Acalabrutinib, Pembrolizumab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 7, 2026, 2:22 AM EST